Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed squamous cell carcinoma of the head and neck, from any primary site. Nasopharyngeal carcinoma, World Health Organization (WHO) Grade I, will be included.~2. Advanced disease, fulfilling one of the criteria defined below:~   * Incurable disease as assessed by surgical or radiation oncology~  * Metastatic (M1) disease~  * Persistent or progressive disease following curative-intent radiation, and not a candidate for surgical salvage due to incurability or morbidity~3. Platinum-refractory or platinum-ineligible, fulfilling one of the criteria defined below:~   * disease progression during or after 4-6 cycles of platinum-containing therapy in the advanced setting~  * disease progression within 6 months of curative-intent treatment, which included platinum-based chemotherapy~  * ineligible for platinum-containing therapy, in the opinion of the medical oncologist, due to medical comorbidities or unacceptable risk for toxicity~  * patient refuses platinum-containing therapy~4. Measurable disease based on response evaluation criteria in solid tumors (RECIST)~   - disease in previously irradiated sites is considered measurable if there has been unequivocal progression of the lesion after radiotherapy, or the lesion contains residual carcinoma by biopsy more than 6 weeks after completion of radiotherapy~5. Easter Cooperative Oncology Group (ECOG) performance status 0-2 at time of informed consent~6. Adequate hematologic reserve and organ function~   * Absolute neutrophil count \> 1200/µl~  * Platelet count \> 100,000/µl~  * Renal function: Serum Creatinine ≤ 1.5x upper limit of normal (ULN)~  * Liver function: Total bilirubin ≤ 1.5x ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN~7. Able to provide written, voluntary consent~8. Patients with reproductive potential must use an effective contraceptive method.~9. Male or female, age ≥ 18 years~10. Life expectancy ≥ 12 weeks~Exclusion Criteria:~1. Nasopharyngeal primary site, if WHO grade II or III~2. Prior treatment blocking the epidermal growth factor receptor (EGFR), in the advanced disease setting~3. Prior treatment blocking EGFR in the curative-intent setting, if delivered in the previous 6 months~4. Prior treatment with a drug blocking the mammalian target of rapamycin (mTOR)~5. Sensitivity to temsirolimus or erlotinib~6. Uncontrolled metastatic disease of the central nervous system~7. Radiotherapy within the 2 weeks before Cycle 1' Day 1~8. Surgery within the 2 weeks before Cycle 1' Day 1~9. Pregnant or lactating females~10. Myocardial infarction or ischemia within the 6 months preceding study treatment~11. Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications~12. No other concurrent, investigational anti-neoplastic agent will be permitted~13. History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus and Erlotinib (Type: EXPERIMENTAL): Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).